我武生物：皮炎诊断贴剂2贴获药物临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for its "Dermatitis Diagnostic Patch 02" clinical trial application, which is aimed at assisting in the diagnosis of allergic contact dermatitis related to various allergens [1] Group 1 - The product is intended for patch testing to diagnose allergic contact dermatitis associated with substances such as carson, p-phenylenediamine, and formaldehyde [1] - The company will conduct Phase I, II, and III clinical trials, as well as the application for marketing authorization, with results being uncertain [1] - Currently, the company is actively preparing for the Phase I clinical trial and will fulfill its information disclosure obligations based on the progress [1]